FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3035580018> ?p ?o ?g. }

• W3035580018 endingPage "1408" @default.
• W3035580018 startingPage "1408.2" @default.
• W3035580018 abstract "Background: In rheumatoid arthritis (RA), biologics treatment is one of the effective treatment options. On the other hand, the effects of biologics cannot be obtained satisfactorily in all patients, and there are some cases in which treatment is interrupted due to ineffective or adverse events. However, the useful predictive markers of the biologics have not been found in the early phase of treatment in RA. Recently, ultrasound (US) has played a role of sensitive imaging modality in the diagnosis and follow-up of patients with RA. Objectives: In this study, we investigated whether continuation of biologics treatment can be predicted by ultrasonographic findings in the early phase. Methods: Fifty-four RA patients who started the first biologics from September 2016 to December 2018 were included. All the patients were performed clinical examination, blood tests and US examination of hand and foot at baseline, 4, 12, 24, 36 and 52 weeks. US examination was performed on MCP joints, PIP joints, wrist and MTP joints. Results: Among 54 cases, 42 cases were able to continue treatment until one year later, and the continuation rate was 80.8%. Of the 12 patients who discontinued first biologics treatment, 5 were changes to other biologics due to inadequate response, 4 were their wishes, and 3 were adverse events. Multiple regression analysis was performed with treatment continuation as the dependent variable and improvement of CRP, MMP-3, DAS28-CRP, grayscale score and power Doppler score in 4 weeks as explanatory variables. Only improvement of power Doppler score was extracted as a significant predictor (p = 0.045). In the continuation group, the improvement of the power Doppler signal at week 4 was 36% compared with the baseline, compared with 10% in the discontinuation group. Conclusion: The early improvement of power Doppler signal in 4 weeks could be a predictive factor for the continuation of 1-year biological treatment. References: [1]Grassi W, Okano T, Di Geso L, Filippucci E. Imaging in rheumatoid arthritis: options, uses and optimization. Expert Rev Clin Immunol. 2015;11:1131-46. [2]Atzeni F, Talotta R, Masala IF, Bongiovanni S, Boccassini L, Sarzi-Puttini P. Biomarkers in Rheumatoid Arthritis. Isr Med Assoc J. 2017;19:512-6. Table 1. Multivariate regression analysis of predictive factors for continuation of biologics treatment in 1-year. Improvement ratio of 0 to 4 weeks beta P value CRP -0.122 0.465 MMP-3 0.228 0.103 DAS28 CRP 0.280 0.103 Ultrasound grey scale score -0.342 0.119 Ultrasound power Doppler score 0.442 0.045 Acknowledgments: We thank Emi Yamashita, Yuko Yoshida, Asami Fujii and Shingo Washida who performed ultrasound examination. Disclosure of Interests: Tadashi Okano Grant/research support from: AbbVie, Eisai, Mitsubishi Tanabe Pharma Corporation and Nipponkayaku, Speakers bureau: AbbVie, Asahikasei, Astellas Pharma Inc, Ayumi Pharmaceutical, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiich Sankyo, Eisai, Janssen, Lilly, Mitsubishi Tanabe Pharma Corporation, Novartis Pharma, Ono Pharmaceutical, Pfizer, Sanofi, Takeda Pharmaceutical, Teijin Pharma and UCB, Kenji Mamoto: None declared, Yutaro Yamada: None declared, Koji Mandai: None declared, Shohei Anno: None declared, Kentaro Inui Grant/research support from: Janssen Pharmaceutical K.K., Astellas Pharma Inc., Sanofi K.K., Abbvie GK, Takeda Pharmaceutical Co. Ltd., QOL RD Co. Ltd., Mitsubishi Tanabe Pharma, Ono Pharmaceutical Co. Ltd., Eisai Co.,Ltd.,, Speakers bureau: Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma, Janssen Pharmaceutical K.K., Astellas Pharma Inc., Takeda Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Abbvie GK, Pfizer Inc., Eisai Co.,Ltd., Chugai Pharmaceutical Co., Ltd., Tatsuya Koike Grant/research support from: AbbVie, Astellas Pharma Inc, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Janssen, Lilly, Mitsubishi Tanabe Pharma Corporation, MSD, Ono Pharmaceutical, Pfizer, Roche, Takeda Pharmaceutical, Teijin Pharma, and UCB, Speakers bureau: AbbVie, Astellas Pharma Inc, Bristol-Myers Squibb, Chugai Pharmaceutical, Eisai, Janssen, Lilly, Mitsubishi Tanabe Pharma Corporation, MSD, Ono Pharmaceutical, Pfizer, Roche, Takeda Pharmaceutical, Teijin Pharma, and UCB, Hiroaki Nakamura Grant/research support from: Astellas Pharma Inc. and Asahi Kasei Pharma Co." @default.
• W3035580018 created "2020-06-19" @default.
• W3035580018 creator A5026239663 @default.
• W3035580018 creator A5048478528 @default.
• W3035580018 creator A5056011991 @default.
• W3035580018 creator A5068092904 @default.
• W3035580018 creator A5074232917 @default.
• W3035580018 creator A5074923100 @default.
• W3035580018 creator A5086343918 @default.
• W3035580018 creator A5089728559 @default.
• W3035580018 date "2020-06-01" @default.
• W3035580018 modified "2023-09-26" @default.
• W3035580018 title "AB0215 EARLY IMPROVEMENT OF THE POWER DOPPLER SIGNAL CAN PREDICT TO CONTINUE THE BIOLOGICAL DMARDS AFTER 1 YEAR." @default.
• W3035580018 doi "https://doi.org/10.1136/annrheumdis-2020-eular.2794" @default.
• W3035580018 hasPublicationYear "2020" @default.
• W3035580018 type Work @default.
• W3035580018 sameAs 3035580018 @default.
• W3035580018 citedByCount "0" @default.
• W3035580018 crossrefType "journal-article" @default.
• W3035580018 hasAuthorship W3035580018A5026239663 @default.
• W3035580018 hasAuthorship W3035580018A5048478528 @default.
• W3035580018 hasAuthorship W3035580018A5056011991 @default.
• W3035580018 hasAuthorship W3035580018A5068092904 @default.
• W3035580018 hasAuthorship W3035580018A5074232917 @default.
• W3035580018 hasAuthorship W3035580018A5074923100 @default.
• W3035580018 hasAuthorship W3035580018A5086343918 @default.
• W3035580018 hasAuthorship W3035580018A5089728559 @default.
• W3035580018 hasBestOaLocation W30355800181 @default.
• W3035580018 hasConcept C126322002 @default.
• W3035580018 hasConcept C126838900 @default.
• W3035580018 hasConcept C141071460 @default.
• W3035580018 hasConcept C143753070 @default.
• W3035580018 hasConcept C197934379 @default.
• W3035580018 hasConcept C2777575956 @default.
• W3035580018 hasConcept C2779244835 @default.
• W3035580018 hasConcept C3017675446 @default.
• W3035580018 hasConcept C527108885 @default.
• W3035580018 hasConcept C71924100 @default.
• W3035580018 hasConceptScore W3035580018C126322002 @default.
• W3035580018 hasConceptScore W3035580018C126838900 @default.
• W3035580018 hasConceptScore W3035580018C141071460 @default.
• W3035580018 hasConceptScore W3035580018C143753070 @default.
• W3035580018 hasConceptScore W3035580018C197934379 @default.
• W3035580018 hasConceptScore W3035580018C2777575956 @default.
• W3035580018 hasConceptScore W3035580018C2779244835 @default.
• W3035580018 hasConceptScore W3035580018C3017675446 @default.
• W3035580018 hasConceptScore W3035580018C527108885 @default.
• W3035580018 hasConceptScore W3035580018C71924100 @default.
• W3035580018 hasIssue "Suppl 1" @default.
• W3035580018 hasLocation W30355800181 @default.
• W3035580018 hasOpenAccess W3035580018 @default.
• W3035580018 hasPrimaryLocation W30355800181 @default.
• W3035580018 hasRelatedWork W190105463 @default.
• W3035580018 hasRelatedWork W2146088809 @default.
• W3035580018 hasRelatedWork W2399380222 @default.
• W3035580018 hasRelatedWork W2411299082 @default.
• W3035580018 hasRelatedWork W2570434461 @default.
• W3035580018 hasRelatedWork W2573667359 @default.
• W3035580018 hasRelatedWork W2977378601 @default.
• W3035580018 hasRelatedWork W3019647602 @default.
• W3035580018 hasRelatedWork W3202305899 @default.
• W3035580018 hasRelatedWork W4362708521 @default.
• W3035580018 hasVolume "79" @default.
• W3035580018 isParatext "false" @default.
• W3035580018 isRetracted "false" @default.
• W3035580018 magId "3035580018" @default.
• W3035580018 workType "article" @default.